Gene · 833
Papers4,113
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
1,201 to 1,220 of 4,113
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Chimeric antigen receptor T cells engineered to recognize the P329G-mutated Fc part of effector-silenced tumor antigen-targeting human IgG1 antibodies enable modular targeting of solid tumors. | J Immunother Cancer | 2022 | 35902133 | PubTator, text mining | PubMed |
| CD7 CAR: sword and shield. | Blood | 2022 | 35900789 | PubTator, text mining | PubMed |
| Trogocytosis and fratricide killing impede MSLN-directed CAR T cell functionality. | Oncoimmunology | 2022 | 35898704 | PubTator, text mining | PubMed |
| Developing ROR1 Targeting CAR-T Cells against Solid Tumors in Preclinical Studies. | Cancers (Basel) | 2022 | 35892876 | PubTator, text mining | PubMed |
| Non-Canonical Programmed Cell Death in Colon Cancer. | Cancers (Basel) | 2022 | 35884370 | PubTator, text mining | PubMed |
| Ferroptosis-Related Genes Are Potential Therapeutic Targets and the Model of These Genes Influences Overall Survival of NSCLC Patients. | Cells | 2022 | 35883650 | PubTator, text mining | PubMed |
| Advances in MUC1-Mediated Breast Cancer Immunotherapy. | Biomolecules | 2022 | 35883508 | PubTator, text mining | PubMed |
| Indomethacin-induced oxidative stress enhances death receptor 5 signaling and sensitizes tumor cells to adoptive T-cell therapy. | J Immunother Cancer | 2022 | 35882449 | PubTator, text mining | PubMed |
| Multidimensional single-cell analysis identifies a role for CD2-CD58 interactions in clinical antitumor T cell responses. | J Clin Invest | 2022 | 35881486 | PubTator, text mining | PubMed |
| Nonviral mcDNA-mediated bispecific CAR T cells kill tumor cells in an experimental mouse model of hepatocellular carcinoma. | BMC Cancer | 2022 | 35879685 | PubTator, text mining | PubMed |
| Physical and in silico immunopeptidomic profiling of a cancer antigen prostatic acid phosphatase reveals targets enabling TCR isolation. | Proc Natl Acad Sci U S A | 2022 | 35878026 | PubTator, text mining | PubMed |
| The Aminoacyl-tRNA Synthetase and tRNA Expression Levels Are Deregulated in Cancer and Correlate Independently with Patient Survival. | Curr Issues Mol Biol | 2022 | 35877431 | PubTator, text mining | PubMed |
| Challenges in the Treatment of Glioblastoma by Chimeric Antigen Receptor T-Cell Immunotherapy and Possible Solutions. | Front Immunol | 2022 | 35874698 | PubTator, text mining | PubMed |
| Eukaryotic Translation Initiation Factor 5A Independently Predicts Poor Prognosis of Cholangiocarcinoma Patients and Regulates the Ferroptosis and Mitochondrial Apoptosis. | J Oncol | 2022 | 35874632 | PubTator, text mining | PubMed |
| From Anti-HER-2 to Anti-HER-2-CAR-T Cells: An Evolutionary Immunotherapy Approach for Gastric Cancer. | J Inflamm Res | 2022 | 35873388 | PubTator, text mining | PubMed |
| Transgenic expression of IL-7 regulates CAR-T cell metabolism and enhances in vivo persistence against tumor cells. | Sci Rep | 2022 | 35869100 | PubTator, text mining | PubMed |
| Semi-automated approach for generation of biological networks on drug-induced cholestasis, steatosis, hepatitis, and cirrhosis. | Toxicol Res | 2022 | 35865277 | PubTator, text mining | PubMed |
| ROR1-targeting switchable CAR-T cells for cancer therapy. | Oncogene | 2022 | 35859167 | PubTator, text mining | PubMed |
| Approaches towards biomaterial-mediated gene editing for cancer immunotherapy. | Biomater Sci | 2022 | 35858470 | PubTator, text mining | PubMed |
| An optimized bicistronic chimeric antigen receptor against GPC2 or CD276 overcomes heterogeneous expression in neuroblastoma. | J Clin Invest | 2022 | 35852863 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/833/papers?page=61